Literature DB >> 25863112

Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach.

Sirorat Pattanapairoj1, Atit Silsirivanit2, Kanha Muisuk3, Wunchana Seubwai3, Ubon Cha'on2, Kulthida Vaeteewoottacharn2, Kanlayanee Sawanyawisuth2, Danaipong Chetchotsak4, Sopit Wongkham5.   

Abstract

OBJECTIVE: Cholangiocarcinoma (CCA) is usually fatal because of the absence of tests for early detection and lack of effective therapy. Tumor markers with adequate diagnostic values are of clinical significance. This study is aimed to improve the diagnostic power of serum markers using the computational data mining technique to develop a combined diagnostic model that yielded the best diagnostic values for CCA. DESIGN AND METHODS: Eight CCA-associated markers-carcinoembryonic antigen, carbohydrate antigen 19-9, alkaline phosphatase (ALP), and gamma glutamyl transferase, biliary-ALP, mucin5AC, CCA-associated carbohydrate antigen (CCA-CA) and CA-S27-were used as the inputs for the C4.5 decision tree classification model and the selected model was confirmed by ANN analyses. Eight serum markers for CCA were determined in the training set of 85 histologically proven-CCA patients and 82 control subjects. The chosen set of combined markers that gave the best diagnostic values for CCA was then validated in the testing set of 22 CCA patients and 60 controls.
RESULTS: A decision tree diagram built by the C4.5 algorithm suggested the serial analysis of CCA-CA and ALP for distinguishing CCA patients from non-CCA subjects with all diagnostic parameters ≥95%. The combined tests showed a precise diagnosis in the testing set.
CONCLUSIONS: The C4.5 model indicates the combined markers of CCA-CA and ALP that produced the more precise diagnosis for CCA.
Copyright © 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALP; C4.5 decision tree; Combined analysis; Hepatobiliary; Mucin; Single neural network; Tumor markers

Mesh:

Substances:

Year:  2015        PMID: 25863112     DOI: 10.1016/j.clinbiochem.2015.03.022

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma.

Authors:  Surangkana Sanmai; Tanakorn Proungvitaya; Temduang Limpaiboon; Daraporn Chua-On; Wunchana Seubwai; Sittiruk Roytrakul; Sopit Wongkham; Chaisiri Wongkham; Ongart Somintara; Sakkarn Sangkhamanon; Siriporn Proungvitaya
Journal:  Oncol Lett       Date:  2019-03-22       Impact factor: 2.967

2.  Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.

Authors:  Gyem Tshering; Palden Wangyel Dorji; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

Review 3.  Artificial intelligence and cholangiocarcinoma: Updates and prospects.

Authors:  Hossein Haghbin; Muhammad Aziz
Journal:  World J Clin Oncol       Date:  2022-02-24

4.  High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma.

Authors:  Muntinee Lertpanprom; Atit Silsirivanit; Patcharaporn Tippayawat; Tanakorn Proungvitaya; Sittiruk Roytrakul; Siriporn Proungvitaya
Journal:  Front Public Health       Date:  2022-08-01

Review 5.  Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Bin Liang; Liansheng Zhong; Qun He; Shaocheng Wang; Zhongcheng Pan; Tianjiao Wang; Yujie Zhao
Journal:  Med Sci Monit       Date:  2015-11-18

6.  Establishment of a Potential Serum Biomarker Panel for the Diagnosis and Prognosis of Cholangiocarcinoma Using Decision Tree Algorithms.

Authors:  Phongsaran Kimawaha; Apinya Jusakul; Prem Junsawang; Raynoo Thanan; Attapol Titapun; Narong Khuntikeo; Anchalee Techasen
Journal:  Diagnostics (Basel)       Date:  2021-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.